Voyager Therapeutics stock hits 52-week low at $2.81

Voyager Therapeutics, Inc. (NASDAQ:VYGR) stock has reached a 52-week low, touching down at $2.81. According to InvestingPro data, technical indicators suggest the stock is in oversold territory, with a strong current ratio of 5.56 indicating solid short-term financial health. This latest price point reflects a significant downturn for the biotechnology company, which specializes in developing treatments for severe neurological diseases. Over the past year, Voyager Therapeutics has seen its stock value decrease sharply, with a 1-year change showing a decline of -67.72%. Despite the decline, the company maintains a strong balance sheet with more cash than debt, and InvestingPro analysis suggests the stock may be undervalued at current levels. This substantial drop underscores the challenges the company has faced in the market, despite ongoing efforts to advance its research and development pipeline. Notably, four analysts have recently revised their earnings expectations upward for the upcoming period. Investors are closely monitoring Voyager's strategic moves to recover from this low and potentially capitalize on its innovative gene therapy programs. For deeper insights into VYGR's potential, access the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Voyager Therapeutics has presented promising preclinical data on its Alzheimer's therapies, including the tau silencing gene therapy VY1706 and the anti-tau antibody VY7523. The findings, shared at an international conference, indicate a significant reduction in tau mRNA and protein levels in non-human primates, with the therapy showing a good safety profile. Voyager plans to file an Investigational New Drug application for VY1706 in 2026. Analyst firms have also weighed in on Voyager's prospects. Canaccord Genuity maintained a Buy rating but lowered its price target to $12, citing adjustments in its valuation model after the company's recent program changes. H.C. Wainwright reiterated a Buy rating with a $30 price target, emphasizing Voyager's strategic partnerships and financial stability. Truist Securities also reaffirmed a Buy rating with an $18 target, noting confidence in the company's broader capsid platform despite setbacks with a specific drug candidate. Meanwhile, Citi adjusted its price target to $11 while maintaining a Buy rating, highlighting the clean safety profile of the VY7523 antibody.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.